Liujia Mian Changrongpian (六甲蜜胺肠溶片)六甲蜜胺肠溶片
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 天津力生制药股份有限公司Chinese legal name: 天津力生制药股份有限公司
主要成分Active Ingredients
- 六甲蜜胺Liujia Mian
药物知识说明
六甲蜜胺是一种在国家药监局注册认定的药品。该药品含有六甲蜜胺-a04544fa等成分。
该药品关联的活性成分包括：六甲蜜胺Liujia Mian。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：天津力生制药股份有限公司Chinese legal name: 天津力生制药股份有限公司。
您可以探索含有相同成分的其他药品：六甲蜜胺-a04544fa成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 六甲蜜胺肠溶片) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 六甲蜜胺Liujia Mian.
Manufacturers recorded for this product: 天津力生制药股份有限公司Chinese legal name: 天津力生制药股份有限公司.
Explore other medicines containing the same ingredient: 六甲蜜胺 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 六甲蜜胺肠溶片Recorded Chinese name: 六甲蜜胺肠溶片
- 剂型Dosage form: 片剂Tablets
- 规格Specification: 0.1g*12片0.1 g × 12 tablets
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 天津力生制药股份有限公司Chinese legal name: 天津力生制药股份有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H12021019
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H12021019
Manufacturer
Chinese legal name: 天津力生制药股份有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
0.1 g × 12 tablets
中文说明书原文Original Chinese source label
批准文号
国药准字H12021019
生产企业
天津力生制药股份有限公司(国产)
适应症
本品用于卵巢癌、小细胞肺癌、恶性淋巴瘤、乳腺癌、骨髓癌的联合化疗.
用法用量
口服。1.单药口服:按体表面积每日150～300mg/m2,分3～4次口服或睡前顿服,连服14天～21天为一疗程,休息2～3周开始下一疗程。2.联合应用口服:按体表面积每日100～200mg/m2,分次口服或睡前顿服,连服14天,休息1周为1个疗程。
不良反应
1.严重恶心呕吐为剂量限制性毒性,骨髓抑制轻至中度,以白细胞降低为著,多发生于治疗一周后,2～4周达最低点。|2.中枢或周围神经毒性出现于长期服用后,为剂量限制性毒性,停药4～5个月可减轻或消失。|3.偶有脱发、膀胱炎、皮疹、瘙痒、体重减轻等。
禁忌
1.对本品过敏者禁用。|2.严重骨髓抑制和神经毒性患者禁用。
注意事项
用药期间应定期查血象及肝功能。
贮藏
遮光，密封保存
规格
0.1g*12片
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.